Welcome to Paid Research Studies




  • Conditions:   Type2 Diabetes;   Obesity
    Intervention:   Behavioral: TRF
    Sponsors:   University of Adelaide;   University of South Australia;   Salk Institute for Biological Studies
    Recruiting

  • Condition:   PreDiabetes
    Interventions:   Other: Intermittent Fasting (IF);   Other: Daily Restriction (DR);   Other: standard care (SC)
    Sponsors:   University of Adelaide;   Salk Institute for Biological Studies
    Recruiting

  • Condition:   Type 2 Diabetes
    Intervention:   Other: Blueberry Tea
    Sponsor:   Menzies Institute for Medical Research
    Recruiting

  • Conditions:   Pre Diabetes;   Type 2 Diabetes Mellitus
    Interventions:   Drug: Metformin + Healthy diet;   Drug: Metformin + Personalized diet
    Sponsors:   Garvan Institute of Medical Research;   Weizmann Institute of Science
    Recruiting

  • Conditions:   Diabetes Mellitus, Type II;   Insulin Resistance
    Interventions:   Procedure: HBO;   Procedure: Hyperbaric air
    Sponsors:   University of Adelaide;   Royal Adelaide Hospital
    Recruiting

  • Conditions:   Poor Glycemic Control;   Cardiovascular Risk Factors;   Cognitive Function 1, Social
    Interventions:   Dietary Supplement: carnosine;   Drug: Placebo
    Sponsor:   Monash University
    Recruiting

  • Conditions:   Metabolic Syndrome;   Type 2 Diabetes Mellitus;   Obesity
    Interventions:   Drug: Empagliflozin Oral Tablet [Jardiance];   Drug: Placebo Oral Tablet
    Sponsor:   Royal Perth Hospital
    Recruiting

  • Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: LY900014;   Drug: Insulin Lispro
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Condition:   Hypertension
    Interventions:   Device: Renal Denervation;   Other: Sham control
    Sponsor:   Baker IDI Heart and Diabetes Institute
    Recruiting

  • Conditions:   Diabetes;   Diabetes Mellitus, Type 1
    Interventions:   Drug: Insulin degludec;   Drug: Insulin Aspart;   Drug: Insulin detemir
    Sponsor:   Novo Nordisk A/S
    Recruiting

  • Condition:   Major Depressive Disorder
    Intervention:   Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
    Sponsors:   Baker IDI Heart and Diabetes Institute;   The Alfred;   Monash Medical Centre;   Ballarat Health Services
    Recruiting

  • Conditions:   Cystic Fibrosis;   Diabetes
    Intervention:   Drug: Once-daily insulin detemir
    Sponsors:   Sydney Children's Hospitals Network;   John Hunter Children's Hospital;   Lady Cilento Children's Hospital, Brisbane;   Women's and Children's Hospital, Adelaide
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
    Sponsor:   Novo Nordisk A/S
    Not yet recruiting

  • Condition:   Heart Failure-Type 2 Diabetes Mellitus
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting

  • Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   Insulin Resistance
    Interventions:   Other: Mixed Meal Challenge;   Other: Glucose Challenge
    Sponsor:   Menzies Institute for Medical Research
    Recruiting

  • Condition:   Diabetes Mellitus, Type 1
    Intervention:  
    Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Allergy and Infectious Diseases (NIAID);   National Center for Research Resources (NCRR);   Juvenile Diabetes Research Foundation;   American Diabetes Association
    Recruiting

  • Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting

  • Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Drug: Zoledronic acid;   Drug: Placebo
    Sponsor:   Austin Health
    Recruiting

  • Conditions:   Pancreatitis, Chronic;   Pancreatitis, Acute
    Interventions:   Diagnostic Test: Blood sample;   Behavioral: Patient questionnaires
    Sponsors:   Aliye Uc;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Glipizide 5 MG
    Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
    Recruiting

  • Conditions:   Independent Living;   Disability Free Survival;   Elderly;   Healthy
    Interventions:   Drug: Atorvastatin;   Drug: Placebo (for Atorvastatin)
    Sponsors:   Monash University;   National Health and Medical Research Council, Australia;   National Heart Foundation, Australia
    Recruiting

  • Condition:   Non-Alcoholic Steatohepatitis (NASH)
    Interventions:   Drug: IVA337;   Drug: Placebo
    Sponsor:   Inventiva Pharma
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Condition:   Heart Failure
    Interventions:   Drug: Empagliflozin;   Drug: Placebo
    Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
    Recruiting

  • Condition:   Heart Failure
    Interventions:   Drug: Empagliflozin;   Drug: Placebo
    Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
    Recruiting

  • Condition:   Diabetic Kidney Disease
    Interventions:   Drug: Propagermanium;   Drug: Placebo
    Sponsors:   Dimerix Bioscience Pty Ltd;   IQVIA
    Recruiting

  • Condition:   Gastroparesis
    Intervention:   Drug: Relamorelin 10 μg
    Sponsor:   Allergan
    Recruiting

  • Conditions:   Neuropathic Pain;   Diabetic Nephropathies;   Post Herpetic Neuralgia
    Interventions:   Drug: LAT8881;   Drug: Placebo
    Sponsor:   Lateral Pharma Pty Ltd
    Recruiting

  • Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
    Sponsor:   Intercept Pharmaceuticals
    Recruiting

  • Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Condition:   Solid Tumors
    Interventions:   Biological: Pembrolizumab;   Drug: Standard of Care (SOC)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
    Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
    Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
    Recruiting

  • Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting

  • Condition:   Respiratory Tract Infection
    Interventions:   Biological: Formulation A;   Biological: Formulation B;   Biological: Formulation C;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Anxiety Disorder;   Cognitive/Functional Effects;   Colorectal Cancer;   Depression;   Fatigue;   Psychosocial Effects of Cancer and Its Treatment;   Sleep Disorders;   Excercise
    Interventions:   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: fatigue assessment and management;   Procedure: quality-of-life assessment;   Other: Educational Intervention;   Other: Fitness testing
    Sponsors:   Canadian Cancer Trials Group;   Survivorship Research Group;   Queen's University, Belfast
    Recruiting

  • Condition:   Giant Cell Arteritis (GCA)
    Interventions:   Drug: Upadacitinib;   Drug: Corticosteroid (CS);   Other: Placebo
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Ulcerative Colitis (UC)
    Intervention:  
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: Mirikizumab;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Condition:   Duchenne Muscular Dystrophy
    Interventions:   Drug: Vamorolone;   Drug: Prednisone;   Other: Placebo
    Sponsors:   ReveraGen BioPharma, Inc.;   European Union;   Cooperative International Neuromuscular Research Group;   Newcastle University;   University of Pittsburgh
    Recruiting

  • Condition:   Cervical Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Placebo to pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Heart Failure
    Intervention:   Device: MPP
    Sponsor:   Abbott Medical Devices
    Recruiting

  • Condition:   Athletes With Isolated Non-ischemic LGE With no Underlying "Labelled" Cardiomyopathy
    Intervention:   Other: non-ischemic scar
    Sponsor:   Rennes University Hospital
    Recruiting

  • Condition:   Psoriatic Arthritis
    Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Hypercholesterolemia
    Interventions:   Drug: Evinacumab;   Drug: Matching placebo;   Other: Background Lipid Modifying Therapy (LMT)
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting

  • Conditions:   Hypercholesterolaemia;   Pregnancy
    Intervention:  
    Sponsor:   Amgen
    Recruiting

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Lorlatinib;   Drug: Crizotinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting